NCT03769935View on ClinicalTrials.gov

Maintenance Therapy for Small-cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

January 1, 2022

Study Completion Date

July 1, 2022

Conditions
Progression Free Survival
Interventions
DRUG

cis Platinum, etoposide, S1

"cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.~S1 25 mg/m2 oral, everyday until progression disease"

Trial Locations (1)

266042

Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao

All Listed Sponsors
lead

Qingdao Central Hospital

OTHER

NCT03769935 - Maintenance Therapy for Small-cell Lung Cancer | Biotech Hunter | Biotech Hunter